Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but Not CCR5 receptor blockers

AIDS Research and Human Retroviruses

Volumn 28, Issue 12, 2012, Pages 1584-1593

  Chatziandreou, Nikolaos ^a   Arauz, Ana Belen ^a   Freitas, Ines ^a   Nyein, Phyu Hninn ^a   Fenton, Gregory ^a   Mehta, Shruti H ^b,c   Kirk, Gregory D ^b,c   Sagar, Manish ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; HYBRID PROTEIN; SOLUBLE CD4 ANTIGEN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IC 50; IN VITRO STUDY; LONGITUDINAL STUDY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SENSITIVITY ANALYSIS; SEROCONVERSION; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; RECEPTORS, HIV; SERIAL PASSAGE;

EID: 84870035855     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0319     Document Type: Article

References (52)

1. Coffin JM: HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-489.
2. Kearney M, Palmer S, Maldarelli F, et al.: Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 2008;22:497-501.
3. Cornelissen M, van den Burg R, Zorgdrager F, Lukashov V, and Goudsmit J: pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol 1997;71:6348-6358.
4. Kozal MJ, Shah N, Shen N, et al.: Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996;2:753-759.
5. Lech WJ, Wang G, Yang YL, et al.: In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996;70:2038-2043.
6. Mohri H, Singh MK, Ching WT, and Ho DD: Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Natl Acad Sci USA 1993;90:25-29.
7. Najera I, Holguin A, Quinones-Mateu ME, et al.: Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995;69:23-31.
8. Back NK, Nijhuis M, Keulen W, et al.: Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a pro-cessivity defect of the reverse transcriptase enzyme. EMBO J 1996;15:4040-4049.
9. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, and Lamarre D: Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997;71:1089-1096.
10. Gerondelis P, Archer RH, Palaniappan C, et al.: The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5¢-end-and DNA 3¢-end-directed RNase H activities. J Virol 1999;73:5803-5813.
11. Archer RH, Dykes C, Gerondelis P, et al.: Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol 2000; 74:8390-8401.
12. Martinez-Picado J, Savara AV, Sutton L, and D'Aquila RT: Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999;73:3744-3752.
13. Martinez-Picado J and Martinez MA: HIV-1 reverse tran-scriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. Virus Res 2008;134:104-123.
14. Li JZ, Paredes R, Ribaudo HJ, et al.: Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based anti-retroviral treatment failure: A systematic review and pooled analysis. JAMA 2011;305:1327-1335.
15. Sagar M: HIV-1 transmission biology: Selection and characteristics of infecting viruses. J Infect Dis 2010;202(Suppl 2):S289-296.
16. Shankarappa R, Margolick JB, Gange SJ, et al.: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999;73:10489-10502.
17. Scarlatti G, Tresoldi E, Bjorndal A, et al.: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997;3:1259-1265.
18. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
19. Brumme ZL, Goodrich J, Mayer HB, et al.: Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005;192:466-474.
20. Moyle GJ, Wildfire A, Mandalia S, et al.: Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005;191:866-872.
21. Etemad B, Fellows A, Kwambana B, et al.: Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J Virol 2009; 83:9694-9708.
22. Repits J, Oberg M, Esbjornsson J, et al.: Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol 2005;86:2859-2869.
23. Koning FA, Kwa D, Boeser-Nunnink B, et al.: Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and-secreted) neutralization of CC chemo-kine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J Infect Dis 2003;188:864-872.
24. Jansson M, Popovic M, Karlsson A, et al.: Sensitivity to inhibition by beta-chemokines correlates with biological phe-notypes of primary HIV-1 isolates. Proc Natl Acad Sci USA 1996;93:15382-15387.
25. Koning FA, Koevoets C, van der Vorst TJ, and Schuitemaker H: Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors. Antivir Ther 2005;10:231-237.
26. Rusert P, Kuster H, Joos B, et al.: Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol 2005;79:8454-8469.
27. Sagar M, Kirkegaard E, Lavreys L, and Overbaugh J: Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Res Hum Retroviruses 2006; 22:430-437.
28. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
29. Tsibris AM, Sagar M, Gulick RM, et al.: In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008;82:8210-8214.
30. Henrich TP, Tsibris A, Lewine N, et al.: Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J Acquir Immune Defic 2010;55:420-427.
31. Vlahov D, Graham N, Hoover D, et al.: Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: Plasma viral load and CD4+ cell count. JAMA 1998;279:35-40.
32. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008;105:7552-7557.
33. Marozsan AJ and Arts EJ: Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates. J Virol Methods 2003;111:111-120.
34. Dudley DM, Gao Y, Nelson KN, et al.: A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques 2009;46:458-467.
35. Wei X, Decker JM, Liu H, et al.: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46:1896-1905.
36. Bjorndal A, Deng H, Jansson M, et al.: Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997;71:7478-7487.
37. Hatch SC, Archer J, and Gummuluru S: Glycosphingolipid composition of human immunodeficiency virus type 1 (HIV-1) particles is a crucial determinant for dendritic cell-mediated HIV-1 trans-infection. J Virol 2009;83:3496-3506.
38. Voronin Y, Chohan B, Emerman M, and Overbaugh J: Primary isolates of human immunodeficiency virus type 1 are usually dominated by the major variants found in blood. J Virol 2007;81:10232-10241.
39. Coetzer M, Nedellec R, Salkowitz J, et al.: Evolution of CCR5 use before and during coreceptor switching. J Virol 2008; 82:11758-11766.
40. Trkola A, Kuhmann SE, Strizki JM, et al.: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002;99:395-400.
41. Kuhmann SE, Pugach P, Kunstman KJ, et al.: Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004; 78:2790-2807.
42. Reeves JD, Gallo SA, Ahmad N, et al.: Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002;99:16249-16254.
43. Reeves JD, Miamidian JL, Biscone MJ, et al.: Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol 2004;78:5476-5485.
44. Xu L, Pozniak A, Wildfire A, et al.: Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005;49:1113-1119.
45. Moore JP and Kuritzkes DR: A piece de resistance: How HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS 2009;4:118-124.
46. Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, and Kuhmann SE: HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007;361:212-228.
47. Ogert RA, Wojcik L, Buontempo C, et al.: Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008;373:387-399.
48. Westby M, Smith-Burchnell C, Mori J, et al.: Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007;81:2359-2371.
49. Alkhatib G, Locati M, Kennedy PE, Murphy PM, and Berger EA: HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: Independence from G protein signaling and importance of coreceptor downmodulation. Virology 1997;234:340-348.
50. Pastore C, Picchio GR, Galimi F, et al.: Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob Agents Chemother 2003;47:509-517.
51. Lobritz MA, Marozsan AJ, Troyer RM, and Arts EJ: Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol 2007;81:8258-8269.
52. Salazar-Gonzalez JF, Bailes E, Pham KT, et al.: Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008;82:3952-3970.